Live Breaking News & Updates on Gynecologic Program

Stay updated with breaking news from Gynecologic program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Keytruda Plus Chemo Improves Progression-Free Survival in Cervical Cancer

The addition of Keytruda to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer. ....

United States , Domenica Lorusso , Us Oncology Research Network , Drug Administration , Catholic University Of Rome , University Of Arizona College Medicine , Gynecologic Program , Adding Keytruda , Catholic University , Arizona College , Research Network , American Indian , Alaska Native , Native Hawaiian , Pacific Islander , Biologics License Application , Prescription Drug User Fee Act , Esmo 2023 , Cervical Cancer , Gynecologic Cancer ,

Keytruda Plus Chemoradiotherapy Bests Standard of Care in Advanced Cervical Cancer

Adding Keytruda to EBRT and chemotherapy, followed by brachytherapy, improved progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer. ....

Domenica Lorusso , Us Oncology Research Network , International Federation Of Gynecology , Division Of Gynecologic Oncology , Gynecologic Program , University Of Arizona College Medicine , Catholic University Of Rome , Adding Keytruda , Gynecologic Oncology , Arizona College , Research Network , International Federation , Catholic University , Expected Safety Profile , Life Core , Biologics License Application , Prescription Drug User Fee Act , Cervical Cancer ,

Pembrolizumab Plus Chemoradiotherapy Shows Statistically Significant PFS Benefit vs SOC in High-Risk Locally Advanced Cervical Cancer

The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival when compared with placebo plus EBRT/chemoradiotherapy/brachytherapy in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer. ....

United States , Domenica Lorusso , International Federation Of Gynecology , Gynecologic Program , Catholic University Of Rome , University Of Arizona College Medicine , Merck Co , Us Oncology Research Network , Speaker Bureau At Astrazeneca , Division Of Gynecologic Oncology , Gynecologic Oncology , Arizona College , Research Network , International Federation , Catholic University , Multiple Races , American Indian , Alaska Native , Native Hawaiian , Expected Safety , Life Core , Biologics License Application , Prescription Drug User Fee Act ,

Avutometinib/Defactinib Combo Generates Early Efficacy Signals in Low-Grade Serous Ovarian Cancer

Bradley J. Monk, MD, FACS, FACOG, discusses the rationale for investigating avutometinib plus defactinib in patients with low-grade serous ovarian cancer, key findings from RAMP 201, and how this research may influence the ovarian cancer treatment paradigm going forward ....

University Of Arizona , United States , City Of , United Kingdom , Susana Banerjee , Creighton University School Of Medicine At St , Gynecologic Program , University Of Arizona College Medicine , Us Oncology Research Network , Gynecologic Oncology , Arizona Oncology , Arizona College , Creighton University School , Research Network , Royal Marsden ,

Dr Monk on Avutometinib Plus Defactinib in Low-Grade Serous Ovarian Cancer

Bradley Monk, MD, FACS, FACOG, discusses findings from the phase 2 RAMP 201 trial in patients with low-grade serous ovarian cancer and the importance of these results within the context of the larger ovarian cancer treatment paradigm. ....

United States , University Of Arizona , Division Of Gynecologic Oncology , University Of Arizona College Medicine , Us Oncology Research Network , Arizona Oncology Us Network , Creighton University School Of Medicine At St , Gynecologic Program , Bradley Monk , Gynecologic Oncology , Arizona Oncology , Arizona College , Creighton University School , Research Network , Ramp 201 Trial , Patients With Low Grade Serous Ovarian Cancer , Us Oncology Network , Creighton University School Of Medicine At St Josephs Hospital , The Gog Foundation , Gog Partners , Avutometinib Plus Defactinib ,